These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 24249923)
1. Metabolic syndrome in schizophrenia. Malhotra N; Grover S; Chakrabarti S; Kulhara P Indian J Psychol Med; 2013 Jul; 35(3):227-40. PubMed ID: 24249923 [TBL] [Abstract][Full Text] [Related]
2. Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients. Chadda RK; Ramshankar P; Deb KS; Sood M J Pharmacol Pharmacother; 2013 Jul; 4(3):176-86. PubMed ID: 23960422 [TBL] [Abstract][Full Text] [Related]
3. The prevalence of metabolic syndrome and its association with alanine aminotransferase in clozapine-treated Korean patients with schizophrenia. Lee NY; Roh MS; Kim SH; Jung DC; Yu HY; Sung KH; Chung IW; Youn T; Kang UG; Ahn YM; Kim YS Int Clin Psychopharmacol; 2013 Mar; 28(2):71-9. PubMed ID: 23211493 [TBL] [Abstract][Full Text] [Related]
4. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. De Hert M; Schreurs V; Sweers K; Van Eyck D; Hanssens L; Sinko S; Wampers M; Scheen A; Peuskens J; van Winkel R Schizophr Res; 2008 Apr; 101(1-3):295-303. PubMed ID: 18299188 [TBL] [Abstract][Full Text] [Related]
5. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study. Bai YM; Chen TT; Yang WS; Chi YC; Lin CC; Liou YJ; Wang YC; Su TP; Chou P; Chen JY Schizophr Res; 2009 Jun; 111(1-3):1-8. PubMed ID: 19409756 [TBL] [Abstract][Full Text] [Related]
6. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. Vancampfort D; Stubbs B; Mitchell AJ; De Hert M; Wampers M; Ward PB; Rosenbaum S; Correll CU World Psychiatry; 2015 Oct; 14(3):339-47. PubMed ID: 26407790 [TBL] [Abstract][Full Text] [Related]
7. Cardiometabolic biomarkers and comorbid metabolic syndrome in schizophrenia: A cross-sectional study of long-term clozapine/olanzapine users. Wang KC; Chan HY; Yang WS; Huang YM; Ho YF; Hwang TJ Asian J Psychiatr; 2024 Dec; 102():104244. PubMed ID: 39298914 [TBL] [Abstract][Full Text] [Related]
8. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study. Wampers M; Hanssens L; van Winkel R; Heald A; Collette J; Peuskens J; Reginster JY; Scheen A; De Hert M Eur Neuropsychopharmacol; 2012 Jan; 22(1):17-26. PubMed ID: 21511441 [TBL] [Abstract][Full Text] [Related]
9. Fatty acid desaturase 1/2 (FADS1 and FADS2), fatty acid desaturase indices, and their relationships with metabolic syndrome in female adults with first-episode schizophrenia after antipsychotic medications. Liu Y; Jin X Psychoneuroendocrinology; 2024 May; 163():106985. PubMed ID: 38394918 [TBL] [Abstract][Full Text] [Related]
10. The relationship between serum adiponectin levels, cardiometabolic indices and metabolic syndrome in schizophrenia. Tay YH; Lee J Asian J Psychiatr; 2019 Jun; 43():1-6. PubMed ID: 31059867 [TBL] [Abstract][Full Text] [Related]
11. Prevalence and predictors of metabolic syndrome in patients with schizophrenia and healthy controls: A study in rural South Indian population. Rawat VS; Ganesh S; Bijjal S; Shanivaram Reddy K; Agarwal V; Devi R; Kumar CN; Christopher R; Thirthalli J Schizophr Res; 2018 Feb; 192():102-107. PubMed ID: 28454923 [TBL] [Abstract][Full Text] [Related]
12. Association between SCAP and SREBF1 gene polymorphisms and metabolic syndrome in schizophrenia patients treated with atypical antipsychotics. Yang L; Chen J; Li Y; Wang Y; Liang S; Shi Y; Shi S; Xu Y World J Biol Psychiatry; 2016 Sep; 17(6):467-74. PubMed ID: 26982812 [TBL] [Abstract][Full Text] [Related]
13. The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone. Lee NY; Kim SH; Jung DC; Kim EY; Yu HY; Sung KH; Kang UG; Ahn YM; Kim YS Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jul; 35(5):1273-8. PubMed ID: 21513765 [TBL] [Abstract][Full Text] [Related]
14. Metabolic adverse effects of olanzapine on cognitive dysfunction: A possible relationship between BDNF and TNF-alpha. Zhang C; Fang X; Yao P; Mao Y; Cai J; Zhang Y; Chen M; Fan W; Tang W; Song L Psychoneuroendocrinology; 2017 Jul; 81():138-143. PubMed ID: 28477447 [TBL] [Abstract][Full Text] [Related]
15. Association Between SIRT1, Cytokines, and Metabolic Syndrome in Schizophrenia Patients With Olanzapine or Clozapine Monotherapy. Fang X; Yu L; Wang D; Chen Y; Wang Y; Wu Z; Liu R; Ren J; Tang W; Zhang C Front Psychiatry; 2020; 11():602121. PubMed ID: 33324265 [No Abstract] [Full Text] [Related]
16. A systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia. Malan-Müller S; Kilian S; van den Heuvel LL; Bardien S; Asmal L; Warnich L; Emsley RA; Hemmings SM; Seedat S Schizophr Res; 2016 Jan; 170(1):1-17. PubMed ID: 26621002 [TBL] [Abstract][Full Text] [Related]
17. Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics. Bai YM; Chen TT; Liou YJ; Hong CJ; Tsai SJ Schizophr Res; 2011 Feb; 125(2-3):179-86. PubMed ID: 21185157 [TBL] [Abstract][Full Text] [Related]
18. Long-Term Treatment with Olanzapine in Hospital Conditions: Prevalence and Predictors of the Metabolic Syndrome. Popović I; Ravanić D; Janković S; Milovanović D; Folić M; Stanojević A; Nenadović M; Ilić M Srp Arh Celok Lek; 2015; 143(11-12):712-8. PubMed ID: 26946767 [TBL] [Abstract][Full Text] [Related]
19. Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review. Sneller MH; de Boer N; Everaars S; Schuurmans M; Guloksuz S; Cahn W; Luykx JJ Front Psychiatry; 2021; 12():625935. PubMed ID: 33868046 [No Abstract] [Full Text] [Related]